Variables | Group I (n = 38) | Group II (n = 33) | p | |
n (%) | n (%) | |||
Age | ||||
Mean ± standard deviation | 46.6 ± 2.1 | 45.1 ± 2.0 | ns | |
Median | 49 | 47 | ||
Interval | 17 - 69 | 22 - 64 | ||
Sex | ||||
Male | 20 (52.6) | 13 (39.4) | ns | |
Female | 18 (47.4) | 20 (60.6) | ||
Underlying diseases | ||||
Acute leukaemia | 7 (18.4) | 8 (24.2) | ns | |
Chronic Leukaemia | 0 | 2 (6.1) | ||
Non-Hodgkin lymphoma | 8 (21.1) | 8 (24.2) | ||
Hodgkin lymphoma | 5 (13.2) | 3 (9.1) | ||
Multiple myeloma | 18 (47.4) | 9 (27.3) | ||
Other | 0 | 3 (9.1) | ||
Hospitalisation (<30 days) | 9 (23.7) | 11 (33.3) | ns | |
Antibiotics (<30 days) | 14 (36.8) | 22 (66.7) | 0.017 | |
Type of transplant | ||||
Autologous | 31 (81.6) | 21 (63.6) | ns | |
Allogeneic | 7 (18.4) | 12 (36.4) | ||
Progenitor cells | ||||
Peripheral blood | 33 (86.8) | 28 (84.8) | ns | |
Bone marrow | 5 (13.2) | 5 (15.2) | ||
Conditioning regimen1 | ||||
Melphalan | 17 (44.7) | 8 (24.3) | ns | |
BEAM | 12 (31.6) | 11 (33.4) | ||
Cyclophosphamide + TBI | 2 (5.3) | 2 (6.0) | ||
Fludarabine + TBI | 2 (5.3) | 4 (12.1) | ||
Busulfan + Cyclophosphamide | 4 (10.5) | 4 (12.1) | ||
Others | 1 (2.6) | 4 (12.1) |